Certolizumab pegol for the treatment of rheumatoid arthritis

Bibliography

• Hochberg MC. Changes in the incidence and prevalence of rheumatoid arthritis in England and Wales, 1970 – 1982. Semin Arthritis Rheum 1990;19:294-302
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997;24:43-8
   PubMed Web of Science ®Google Scholar
• Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108-17
   PubMed Web of Science ®Google Scholar
• Nell VP, Machold KP, Eberl G, Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14
   PubMed Web of Science ®Google Scholar
• van Dongen H, van Aken J, Lard LR, Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;56:1424-32
   PubMed Web of Science ®Google Scholar
• Combe B, Landewe R, Lukas C, EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16
   PubMed Web of Science ®Google Scholar
• Singh JA, Christensen R, Wells GA, Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009(2):CD007848
   Google Scholar
• Kristensen L, Jakobsen A, Bartels E, The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol 2011;40:1-7
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21
   PubMed Web of Science ®Google Scholar
• Hutchinson D, Tier J, Soper S, The conversion of infliximab to adalimumab in stable rheumatoid arthritis patients. Rheumatology 2005;44(Suppl 1): abstract 136
   Google Scholar
• Buch MH, Conaghan PG, Quinn MA, True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis 2004;63:1344-6
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P, Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D Jr, Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11
   PubMed Web of Science ®Google Scholar
• Cimzia (certolizumab pegol) prescribing information. Bethesda, MD: US Food and Drugs Administration, July 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125160s111lbl.pdf [Last accessed 4 December 2011]
   Google Scholar
• EMEA/H/C/001037 -II/0009 - Cimzia: European Public Assessment Report, Summary of Product Characteristics. London, UK: European Medicines Agency. January 2010 (updated February 2011). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf [Last accessed 4 December 2011]
   Google Scholar
• Fossati G, Nesbitt A. Certolizumab pegol has a different profile from the other anti-TNFs, including golimumab, in a variety of in vitro assays. Ann Rheum Dis 2010;69(Suppl 3):324
   Google Scholar
• Tracey D, Klareskog L, Sasso EH, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010;10(3):308-15
   PubMed Web of Science ®Google Scholar
• Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005;36:3-10
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348:36-41
   PubMed Web of Science ®Google Scholar
• Choy EHS, Hazleman B, Smith M, Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 2002;41:1133-7
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Fleischmann R, Van Vollenhoven RF, Certolizumab Pegol as monotherapy or with concomitant DMARDS in patients with active rheumatoid arthritis (RA) with or without prior TNF inhibitor use: Analyses of the REALISTIC 12-week phase IIIB randomised controlled study [abstract]. Ann Rheum Dis 2011;70(Suppl 3):414
   PubMedGoogle Scholar
• Smolen JS, Emery P, Ferraccioli G, Efficacy and safety of certolizumab pegol after incomplete response to DMARDS in RA patients with low to moderate disease activity: Results from CERTAIN, a phase IIIB study (abstract). Ann Rheum Dis 2011;70(Suppl 3):259
   PubMedGoogle Scholar
• Smolen J, van Vollenhoven R, Kavanaugh A, Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis (RA): 3-year data from the RAPID 2 study. Arthritis Rheum 2011;62:797-804
   Google Scholar
• Van der Heijde D, Schiff M, Keystone E, Time to and level of initial DAS28 change with certolizumab pegol predicts the liklihood of having low disease activity at years 1 and 2 in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69(Suppl 3):505
   Google Scholar
• Emery P, Furst D, Keystone E, Certolizumab pegol remains equally efficacious in the treatment of rheumatoid arthritis over a range of background methotrexate regimens (10 – 30 mg/wk): analysis of the RAPID 1 trial. Ann Rheum Dis 2008;67(Suppl 1):180
   Google Scholar
• Fleischmann R, Choy EH, Van Vollenhoven R, Safety, efficacy and sustained improvements in household productivity and daily activities with certolizumab pegol (CZP) monotherapy over two years in patients with active rheumatoid arthritis. Arthritis Rheum 2010;62(Suppl 10):S765
   Google Scholar
• Emery P, Genovese MC, Van Vollenhoven R, Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009;36:1429-41
   PubMed Web of Science ®Google Scholar
• Lacaille D, White MA, Backman CL, Gignac MA. Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. Arthritis Rheum 2007;57:1269-79
   PubMed Web of Science ®Google Scholar
• Tang K, Escorpizo R, Beaton DE, Measuring the impact of arthritis on worker productivity: perspectives, methodologic issues, and contextual factors. J Rheumatol 2011;38:1776-90
   PubMed Web of Science ®Google Scholar
• Escorpizo R, Bombardier C, Boonen A, Worker productivity outcome measures in arthritis. J Rheumatol 2007;34:1372-80
   PubMed Web of Science ®Google Scholar
• Beaton D, Bombardier C, Escorpizo R, Measuring worker productivity: frameworks and measures. J Rheumatol 2009;36:2100-9
   PubMed Web of Science ®Google Scholar
• Kosinski M, Zhao SZ, Dedhiya S, Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Smolen JS, Emery P, Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 2009;61:1592-600
   PubMed Web of Science ®Google Scholar
• Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther 2009;11(3):R73
   PubMed Web of Science ®Google Scholar
• Westhovens R, Strand V, Keystone EC, A faster clinical response to certolizumab pegol treatment is associated with better improvements in household productivity in patients with rheumatoid arthritis (abstract). Arthritis Rheum 2009;60(Suppl 10):721
   Google Scholar
• Strand V, Purcaru O, van Vollenhoven R, Certolizumab pegol monotherapy provides sustained improvements in household productivity and daily activities in patients with active rheumatoid arthritis over 2 years. Ann Rheum Dis 2010;69(Suppl 3):656
   Google Scholar
• van Vollenhoven RF, Smolen JS, Schiff M, Safety update on certolizumab pegol in patients with active rheumatoid arthritis (abstract). Arthritis Rheum 2009;60(Suppl 10):1699
   Google Scholar
• Weinblatt M, Fleischmann R, Emery P, Efficacy and safety of certolizumab pegol in a clinically representative population of patients (pts) with active rheumatoid arthritis (RA): results of the REALISTIC Phase IIIb randomized controlled study. Arthritis Rheum 2010;62:1805
   Google Scholar
• Singh JA, Wells GA, Christensen R, Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794
   PubMed Web of Science ®Google Scholar
• Dixon WG, Symmons DPM, Lunt M, Serious infection following anti–tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904
   PubMed Web of Science ®Google Scholar
• Mariette X, Tubach F, Ravaud P, Patients on anti-TNF have an increased risk of lymphoma compared with the general population. Results of the French RATIO observatory. Ann Rheum Dis 2008;67(Suppl 2):323
   PubMedGoogle Scholar
• Smitten A, Simon T, Hochberg M, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10(2):R45
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M, Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology biologics register. Arthritis Care Res 2010;62:755-63
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Hierse F, Rau R, Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12(1):R5
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-34
   PubMed Web of Science ®Google Scholar
• Porter C, Kopotsha T, Smith B, No significant transfer of certolizumab pegol compared with IgG in the perfused human placenta in vitro (abstract). Ann Rheum Dis 2010;69(Suppl 3):210
   PubMedGoogle Scholar
• Wolf D, Mahadevan U. Certolizumab Pegol use in pregnancy: low levels detected in cord blood [abstract]. Arthritis Rheum 2010;62(Suppl 10):299
   Google Scholar
• Mease PJ. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology 2011;50:261-70
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Jonas BL, The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408
   PubMed Web of Science ®Google Scholar
• Paltiel M, Gober LM, Deng A, Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol 2008;144:1190-4
   PubMed Web of Science ®Google Scholar
• Lamour S, Bracher M, Nesbitt A. The PEG component of certolizumab pegol inhibits degranulation by stimulated mast cells (abstract). Arthritis Rheum 2009;60(Suppl 10):44
   Google Scholar
• Connock M, Tubeuf S, Malottki K, Certolizumab pegol (Cimzia) for the treatment of rheumatoid arthritis. Health Technol Assess 2010;14(Suppl 2):1-10
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007;46:1345-54
   PubMed Web of Science ®Google Scholar
• Purcaru O, Taylor P, Emery P, Palmer S. Cost-effectiveness of certolizumab pegol plus methotrexate or as monotherapy for the treatment of active rheumatoid arthritis in the United Kingdom [abstract]. Ann Rheum Dis 2010;69(Suppl 3):718
   PubMedGoogle Scholar
• Saleem B, Keen H, Goeb V, Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69:1636-42
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Certolizumab pegol for moderate-to-severe Crohn's disease. Gastroenterol Hepatol 2007;4:467-8
   Google Scholar
• Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 2004;71:518-24
   PubMed Web of Science ®Google Scholar
• Maetzel A, Li LC, Pencharz J, Community Hypertension and Arthritis Project Study Team. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401
   PubMed Web of Science ®Google Scholar
• Anis A, Zhang W, Emery P, The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology 2009;48:1283-9
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Cifaldi MA, Ray S, Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res 2010;62:226-34
   Web of Science ®Google Scholar